Michael Bishop

2.3k total citations
43 papers, 1.2k citations indexed

About

Michael Bishop is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Michael Bishop has authored 43 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 17 papers in Oncology and 12 papers in Immunology. Recurrent topics in Michael Bishop's work include Hematopoietic Stem Cell Transplantation (16 papers), CAR-T cell therapy research (13 papers) and Immune Cell Function and Interaction (7 papers). Michael Bishop is often cited by papers focused on Hematopoietic Stem Cell Transplantation (16 papers), CAR-T cell therapy research (13 papers) and Immune Cell Function and Interaction (7 papers). Michael Bishop collaborates with scholars based in United States, Germany and Netherlands. Michael Bishop's co-authors include G Winokur, David L. Porter, Sergio Giralt, Alan S. Wayne, David G. Maloney, Michael Boyiadzis, Nancy M. Hardy, Carl H. June, Crystal L. Mackall and B. V. Rama Sastry and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Michael Bishop

37 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Bishop United States	19	497	463	378	200	173	43	1.2k
Laurie Ford United States	23	457 0.9×	320 0.7×	129 0.3×	110 0.6×	377 2.2×	66	1.2k
Benjamin Gesundheit Israel	18	283 0.6×	178 0.4×	168 0.4×	111 0.6×	130 0.8×	60	967
Theodore S. Johnson United States	16	175 0.4×	475 1.0×	1.2k 3.2×	69 0.3×	333 1.9×	27	2.0k
M.B. Bradley United States	21	498 1.0×	289 0.6×	163 0.4×	130 0.7×	137 0.8×	44	1.3k
Barbara Rooney United States	17	362 0.7×	525 1.1×	833 2.2×	90 0.5×	124 0.7×	19	1.2k
Jocelyn Sendecki United States	19	165 0.3×	448 1.0×	136 0.4×	36 0.2×	191 1.1×	35	1.2k
Hui Fan China	14	176 0.4×	637 1.4×	227 0.6×	153 0.8×	343 2.0×	51	1.0k
Emily Williams United States	11	170 0.3×	285 0.6×	520 1.4×	52 0.3×	419 2.4×	22	1.2k
Carlos S. Alvarado United States	18	229 0.5×	176 0.4×	149 0.4×	164 0.8×	316 1.8×	107	1.2k
Laura Conti Italy	24	231 0.5×	161 0.3×	162 0.4×	31 0.2×	232 1.3×	99	1.7k

Countries citing papers authored by Michael Bishop

Since Specialization

Citations

This map shows the geographic impact of Michael Bishop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Bishop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Bishop more than expected).

Fields of papers citing papers by Michael Bishop

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Bishop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Bishop. The network helps show where Michael Bishop may publish in the future.

Co-authorship network of co-authors of Michael Bishop

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Bishop. A scholar is included among the top collaborators of Michael Bishop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Bishop. Michael Bishop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Frigault, Matthew J., Jacalyn Rosenblatt, Binod Dhakal, et al.. (2024). Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Results From at Least 1-Year Follow-Up in All Patients. Clinical Lymphoma Myeloma & Leukemia. 24. S237–S237. 2 indexed citations

Warner, Allison Betof, Omid Hamid, Krishna V. Komanduri, et al.. (2024). Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. Journal for ImmunoTherapy of Cancer. 12(2). e008735–e008735. 37 indexed citations

Atkins, Michael B., Hamzah Abu‐Sbeih, Paolo A. Ascierto, et al.. (2022). Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). Journal for ImmunoTherapy of Cancer. 10(9). e005413–e005413. 7 indexed citations

Gökbuget, Nicola, Jonathan Canaani, Arnon Nagler, et al.. (2018). Prevention and treatment of relapse after stem cell transplantation with immunotherapy. Bone Marrow Transplantation. 53(6). 664–672. 9 indexed citations

Bevans, Margaret, Sandra A. Mitchell, John Barrett, et al.. (2013). Symptom Distress Predicts Long-Term Health and Well-Being in Allogeneic Stem Cell Transplantation Survivors. Biology of Blood and Marrow Transplantation. 20(3). 387–395. 27 indexed citations

Lima, Marcos de, David L. Porter, Minoo Battiwalla, et al.. (2013). Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation. 20(1). 4–13. 99 indexed citations

Khuu, Hanh, Steven Z. Pavletic, Michael Bishop, et al.. (2013). Analysis of the recovery of cryopreserved and thawed CD34+ and CD3+ cells collected for hematopoietic transplantation. Transfusion. 54(4). 1088–1092. 23 indexed citations

Hardy, Nancy M., Miriam E. Mossoba, Seth M. Steinberg, et al.. (2011). Phase I Trial of Adoptive Cell Transfer with Mixed-Profile Type-I/Type-II Allogeneic T Cells for Metastatic Breast Cancer. Clinical Cancer Research. 17(21). 6878–6887. 12 indexed citations

Bishop, Michael, Edwin P. Alyea, Mitchell S. Cairo, et al.. (2011). National Cancer Institute’s First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Summary and Recommendations from the Organizing Committee. Biology of Blood and Marrow Transplantation. 17(4). 443–454. 31 indexed citations

10.

Baird, Kristin, Terry J. Fry, Seth M. Steinberg, et al.. (2011). Reduced-Intensity Allogeneic Stem Cell Transplantation in Children and Young Adults with Ultrahigh-Risk Pediatric Sarcomas. Biology of Blood and Marrow Transplantation. 18(5). 698–707. 14 indexed citations

11.

Grković, Lana, Kristin Baird, Seth M. Steinberg, et al.. (2011). Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity. Leukemia. 26(4). 633–643. 43 indexed citations

12.

Bevans, Margaret, Sandra A. Mitchell, A. John Barrett, et al.. (2011). Function, Adjustment, Quality of Life and Symptoms (FAQS) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Survivors: A Study Protocol. Health and Quality of Life Outcomes. 9(1). 24–24. 22 indexed citations

13.

Alyea, Edwin P., Daniel J. DeAngelo, John M. Pagel, et al.. (2010). NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention of Relapse Following Allogeneic Cell Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation. 16(8). 1037–1069. 37 indexed citations

14.

Cairo, Mitchell S., Craig T. Jordan, Carlo C. Maley, et al.. (2010). NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biological Considerations of Hematological Relapse following Allogeneic Stem Cell Transplantation Unrelated to Graft-versus-Tumor Effects: State of the Science. Biology of Blood and Marrow Transplantation. 16(6). 709–728. 24 indexed citations

15.

Brink, Marcel R.M. van den, David L. Porter, Sergio Giralt, et al.. (2009). Relapse after Allogeneic Hematopoietic Cell Therapy. Biology of Blood and Marrow Transplantation. 16(1). S138–S145. 70 indexed citations

16.

Boyiadzis, Michael, Sarfraz Memon, Mirosław J. Szczepański, et al.. (2008). Up-regulation of NK Cell Activating Receptors Following Allogeneic Hematopoietic Stem Cell Transplantation under a Lymphodepleting Reduced Intensity Regimen is Associated with Elevated IL-15 Levels. Biology of Blood and Marrow Transplantation. 14(3). 290–300. 61 indexed citations

17.

Hardy, Nancy M., Christine Grady, Rebecca D. Pentz, et al.. (2007). Bioethical considerations of monoclonal B‐cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation. British Journal of Haematology. 139(5). 824–831. 22 indexed citations

18.

Yamashita, Kouhei, Mitchell E. Horwitz, Effie Nomicos, et al.. (2006). Unique Abnormalities of CD4+ and CD8+ Central Memory Cells Associated with Chronic Graft-versus-Host Disease Improve after Extracorporeal Photopheresis. Biology of Blood and Marrow Transplantation. 12(1). 22–30. 16 indexed citations

19.

Khuu, Hanh, Claude Kasten-Sportès, Alan S. Wayne, et al.. (2002). Catastrophic failures of freezing bags for cellular therapy products: description, cause, and consequences. Cytotherapy. 4(6). 539–549. 27 indexed citations

20.

Armitage, J. O., et al.. (1995). AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR HODGKIN'S DISEASE. Journal of Hematotherapy. 4(1). 61–62. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact